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Cardiovascular disease (CVD), a leading cause of death in patients with diabetes mellitus, has several pathogenic mechanisms 
that are well established. However, the traditional hypoglycemic agents do not have proven positive effects on macrovascular dis-
ease. Novel therapeutic agents target the incretin pathway including the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) ago-
nists and the dipeptidyl peptidase-4 inhibitors. The glucose-regulatory actions of these agents function by increasing insulin se-
cretion and suppressing glucagon. They also act to increase weight loss not only by inhibiting gastric emptying, but also by reduc-
ing appetite. Although GLP-1 and GLP-1R agonists have demonstrated beneficial effects on myocardium and vascular endothe-
lium including coronary and peripheral mouse vessels, they also have anti-inflammatory and anti-atherogenic actions. These 
agents also have positive effects on the lipid profile and blood pressure. Although these cardioprotective actions seem to be be-
yond the effects of glucose control and weight loss, they are mediated through GLP-1R- or GLP-1R-independent actions of cleaved 
GLP-1 (9-36). Larger randomized controlled trials are necessary to elucidate the clinical promise of these beneficial CVD effects.
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INTRODUCTION
Patients with diabetes mellitus (DM) have a significantly in-
creased risk of morbidity and mortality associated with not 
only cardiovascular disease (CVD), but also stroke, causing 
75% of all deaths [1]. These patients also have a 3 to 5-fold in-
creased incidence of death from coronary heart disease com-
pared with nondiabetic subjects [2,3]. The pathogenic mecha-
nisms for developing atherosclerosis in DM include endothe-
lial dysfunction, oxidative stress, impaired vasodilation, and 
the increased generation of glycosylated products. Diabetes 
often coexists with other well-established risk factors for CVD 
including hypertension and dyslipidemia. The management of 
hypertension and elevated blood lipid levels is effective in im-
proving cardiovascular outcome. However, little is known re-
garding the long-term and beneficial effects of traditional anti-
diabetic agents on macrovascular disease [4]. In some instanc-
es, the chronic use of hypoglycemic agents may induce nega-
tive cardiovascular outcomes, despite improvement in hyper-
glycemia [5].
  Recently, a novel class of incretin-based hypoglycemic agents 
has been developed. Incretins, gut-derived hormones, pre-
dominantly glucagon-like peptide 1 (GLP-1) and gastric in-
hibitory polypeptide, are released in response to ingested nu-
trients, mainly glucose. Incretins not only stimulate postpran-
dial insulin release from pancreatic β-cells [6] and inhibit glu-
cagon secretion [7,8], but also inhibit gastric emptying [9]. 
Active isoforms of GLP-1 include GLP-1 (7-36) amide and 
GLP-1 (7-37). Approximately 80% of the circulating active 
GLP-1 is GLP-1 (7-36) amide, which is rapidly cleaved by di-
peptidyl peptidase-4 (DPP-4) to GLP-1 (9-36), which does not 
interact with the known GLP-1 receptor [6,10,11]. The GLP-1 
stimulates the glucagon-like peptide 1 receptor (GLP-1R), a G 
protein–coupled receptor that is expressed in islet β-cells. Oth-
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er areas for the GLP-1R include not only the central (hypothal-
amus) and peripheral nervous systems, but also the gastroin-
testinal tract, lung, heart and vasculature [6,12,13]. GLP-1R 
activation stimulates adenylate cyclase, which increases cAMP. 
The increased cAMP activates protein kinase A, which then 
sensitizes the beta cells to glucose-stimulated insulin secretion. 
GLP-1 administration not only produces weight loss associat-
ed with reduced food intake [14,15], but also promotes insulin 
biosynthesis and β-cell proliferation [16,17]. It has also been 
suggested that GLP-1 may have neuroprotective, cardiopro-
tective, and vasodilatory benefits [18]. Apart from the indirect 
effect of GLP-1 on CVD outcomes through improved hyper-
glycemia, there is accumulating evidence from both experimen-
tal and clinical studies suggesting a direct influence on the 
myocardium as well [19,20].
  The present overview considers the pleiotropic actions of 
GLP-1 and GLP-1R agonists on the cardiovascular system in-
cluding risk factors and outcomes.
IMPROVEMENT ON MARKERS OF 
ATHEROSCLEROSIS BY GLP-1 AND GLP-1R 
AGONISTS 
Since the associations of hyperglycemia and dysmetabolism 
with cardiovascular risk have been demonstrated in a number 
of trials [21-23], it would be useful to evaluate whether GLP-1 
and GLP-1R agonists reduce cardiovascular risk. 
  Plasminogen activator inhibitor type-1 (PAI-1) levels have 
been implicated in endothelial cell dysfunction. Liu et al. [24] 
reported that treatment with GLP-1 in human umbilical vein 
endothelial cells (HUVEC) attenuated the ability of tumor ne-
crosis factor-alpha (TNF-α) to induce the PAI-1 gene and its 
protein expression. The above treatment also inhibited Akt 
phosphorylation. In addition, liraglutide, a long-acting GLP-1 
analogue, not only inhibited TNF-α or the hyperglycemia-
mediated induction of PAI-1, the intercellular adhesion mole-
cule-1 and the vascular cell adhesion molecule-1 mRNA, but 
also the protein expression in a human vascular endothelial 
cell [25]. 
  Arakawa et al. [26] reported that the GLP-1R was abundant-
ly expressed in monocytes/macrophages. This finding could 
suggest that GLP-1 can directly act on monocytes or macro-
phages. Continuous infusion of exendin-4, a GLP-1R agonist, 
for 28 days significantly inhibited monocytic adhesion in the 
thoracic aortas of C57BL/6 mice without any change in body 
weight or glucose tolerance. In apoE
-/- mice, exendin-4 not 
only inhibited the monocyte adhesion to the endothelium with 
downregulation of intercellular adhesion molecule-1 (ICAM-
1) and vascular cell adhesion molecule-1 (VCAM-1), it also 
reduced atherosclerotic lesions (Fig. 1). The in vitro treatment 
with exendin-4 suppressed the lipopolysaccharide (LPS)-in-
duced expression of TNF-α and monocyte chemoattractant 
protein-1 (MCP-1) as well as suppressing the LPS-induced 
nuclear translocation of proinflammatory transcriptional nu-
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Fig. 1.  Exendin-4 reduced monocyte adhesion to the endo-
thelium and atherosclerotic lesions in apoE
-/- mice after 28-
day treatment. (A) En face immunohistochemical staining of 
Mac-2 antibody of the aorta (n=7). (B) mRNA expression lev-
els of intercellular adhesion molecule-1 (ICAM-1) and vascu-
lar cell adhesion molecule-1 (VCAM-1) (n=5–7). (C) Aortic 
sinuses stained with oil red O and the mean area of oil red O–
positive lesions (n=20). Data are mean±SEM. 
aP<0.05 vs. con-
trol (Adapted from Arakawa M, et al. Diabetes 2010;59:1030-7) 
[26].
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clear factor-κB (NF-κB) p65 in mouse macrophages. This ef-
fect was completely abolished by MDL-12330A, a cAMP in-
hibitor, and PKI14-22, a protein kinase A–specific inhibitor. 
These results suggest that GLP-1R activation significantly re-
duces monocyte/macrophage accumulation in the vascular 
wall. This activation eventually suppressed atherosclerogenesis 
by inhibiting the inflammatory response in the macrophages 
via the cAMP/PKA pathway.
  In a small randomized study, GLP-1 infusion in 12 patients 
with type 2 DM (T2DM) and stable coronary artery disease 
caused a significant increase in the flow-mediated vasodilation 
(FMD), with no effects on the insulin sensitivity index (ISI). 
These effects were not seen in healthy subjects. These observa-
tions suggest that GLP-1 might potentially improve endotheli-
al dysfunction associated with atherosclerosis but not insulin 
resistance in patients with T2DM [27]. In a recent randomized 
study, 128 T2DM patients who received 12 months of either 
exenatide or glibenclamide showed a significant reduction in 
body weight (-6.3 kg) and a reduction in hs-CRP (-0.4 mg/L), 
a marker of inflammation [28].
  Meier et al. [29] reported that the GLP-1 administration not 
only abolished the postprandial increase in triglyceride level 
(-0.023±0.045 mmol/L, P<0.05), but also suppressed plasma 
fasting and postprandial non-esterified fatty acid (NEFA) con-
centrations by 39% and 31%, respectively (P<0.01), in 14 
healthy male subjects. After 82 weeks of adjunctive exenatide 
treatment in 314 obese diabetics treated with sulfonylurea and/ 
or metformin, there was not only a progressive reduction of 
body weight (-4.4±0.3 kg), a reduction in triglyceride concen-
tration (16%), and a reduction in sitting diastolic blood pres-
sure (-2.7 mm Hg), but also a significant increase in high den-
sity lipoprotein cholesterol (12%) [30]. These observations sug-
gest that, even though GLP-1 might improve postprandial lip-
idemia by delaying gastric emptying, it may also affect the in-
sulin-mediated inhibition of lipolysis. There may also be an 
increase in triglyceride clearance or a reduction in the endog-
enous synthesis of triglycerides [29,31,32]. It is suggested that 
the blood pressure-lowering effect in patients with DM could 
be caused by GLP-1–induced natriuresis [33] and vasodilatory 
effects [18] rather than improved insulin resistance [34]. How-
ever, the effect of GLP-1 and/or GLP-1R agonists on blood 
pressure remains to be determined because conflicting data 
are still being reported [35-38]. 
THE CARDIOPROTECTIVE AND 
VASOACTIVE ACTIONS OF GLP-1 AND GLP-1 
AGONISTS
Since the GLP-1Rs are also expressed in cardiac tissues, it is 
feasible that GLP-1 and GLP-1R agonists may mediate cardiac 
functions. In both the isolated perfused rat heart and the whole 
animal models of ischemia/reperfusion (I/R) [39], treatment 
with GLP-1 before ischemia significantly reduced infarct size. 
The GLP-1R antagonist exendin (9-39) and inhibitors of 
cAMP (Rp-cAMP), phosphoinositide 3-kinases (LY294002), 
and p42/44 mitogen-activated protein kinase (UO126) abol-
ished this effect in both heart models. These data suggest that 
the cardioprotective effects of GLP-1 involve multiple pro-sur-
vival kinases rather than noncardiac effects. Timmers et al. 
[40] examined the efficacy of GLP-1R agonists at reducing in-
farct size in pigs. The administration of exenatide subsequent 
to the I/R reduced infarct size by 40% and improved systolic 
wall thickening, ventricular volumes and myocardial stiffness 
compared with those in the saline controls. These beneficial 
myocardial effects of the GLP-1R agonist were associated with 
the modulation of molecular mechanisms regulating apopto-
sis. Some of these mechanisms include higher levels of phos-
phorylated Akt and bcl-2 expression with lower levels of cas-
pase-3 expression and apoptosis-inducing caspases. Addition-
ally, with modulation of oxidative stress, there are higher levels 
of antioxidant enzymes and reduction of oxidative stress 
markers. These data suggest these beneficial effects of exena-
tide on the myocardium could be associated with reduced 
apoptosis and oxidative stress (Fig. 2).
  There are a number of studies with human subjects that eval-
uated the cardioprotective effects of GLP-1 and GLP-1R ago-
nists. Nikolaidis et al. [41] investigated the 72-hour infusion of 
GLP-1 (1.5 pmol/kg/min) in 10 patients with not only an acute 
myocardial infarction, but also a left ventricular ejection frac-
tion (LVEF) <40%. After a successful primary angioplasty sig-
nificantly improved LVEF (11%) and wall motion score index-
es (21%) compared with those of untreated controls, these im-
provements were maintained for months in some subjects af-
ter cessation of GLP-1 treatment. A 5-week infusion of GLP-1 
(2.5 pmol/kg/min) in 12 patients with New York Heart Asso-
ciation (NYHA) class III/IV heart failure significantly improved 
LVEF, maximum myocardial ventilation oxygen consumption 
(VO2 max), 6-minute walk distance and Minnesota Living 
with Heart Failure Quality of Life score (MNQOL) in both di-440
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abetic and non-diabetic patients. These results indicate that 
GLP-1 administration might improve left ventricular function, 
functional status, and quality of life in patients with severe 
heart failure [42]. 
  Ban et al. [18] localized GLP-1R expression to cardiomyo-
cytes, endothelium and vascular SMCs of the normal adult 
mouse heart and showed that GLP-1 administration not only 
increased glucose uptake and cAMP and cGMP release, but 
also the left ventricular pressure and coronary flow in isolated 
mouse hearts. The effect of GLP-1R also increased the func-
tional recovery and the cardiomyocyte viability after I/R inju-
ry. However, because the increased cAMP might have a long-
term harmful effect in the heart, one must investigate the car-
diovascular effects of GLP-1. Ban et al. next turned their atten-
tion to the role of GLP-1 (9-36), the DPP-4-generated metabo-
lite of GLP-1, to determine if it has an intermediary potential 
action against I/R injury. The administration of GLP-1 (9-36) 
after I/R injury increased vasodilatation and coronary flow in 
wild-type and Glp1r
-/- mice. The administration of NO-syn-
thase inhibitor significantly blocked the vasodilatory effects of 
GLP-1 and GLP-1 (9-36). As shown in Fig. 3, GLP-1 had im-
portant cardiovascular actions through two pathways. One of 
these pathways included a dependence on the GLP-1R for ino-
tropic action, glucose uptake, ischemic preconditioning, and 
mild vasodilatory actions. The second depended on GLP-1 (9-
36) having GLP-1R–independent effects on the post-ischemic 
recovery of cardiac function and vasodilation acting, at least 
in part, through a NOS-dependent cGMP formation. A much 
larger dose of the GLP-1R agonist exendin-4 (5 nmol/L), a po-
tent DPP-4-resistant GLP-1R agonist, was needed to reproduce 
the protective effect of native GLP-1. These data further sug-
gest that the cardioprotective effects of GLP-1 are mediated, at 
least in part, by a GLP-1R–independent effect of GLP-1 (9-36) 
[43].
Fig. 2.  Exenatide treatment after 75 minutes of coronary ar-
tery ligation and subsequent reperfusion in pigs. Myocardial 
infarct size quantification as a percentage of the area at risk 
(AAR) (A) and as a percentage of the total left ventricle (LV) 
(B). PBS (n=9); exenatide (n=9). Representative pictures after 
Evans blue and triphenyltetrazolium chloride (C, D). Blue in-
dicates non-threatened myocardium, red indicates the nonin-
farcted area within the area at risk, and white indicates myo-
cardial infarction. Quantifications of immunostaining for 8-hy-
droxydeoxy-guanosine (E) and terminal deoxynucleotidyl 
transferase biotin-dUTP nick end labeling (TUNEL) assay (F) 
(Adapted from Gill A, et al. Cardiovasc Diabetol 2010;9:6) [38].
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Fig. 3.  Physiological cardioprotective actions (A) and proposed 
mechanisms of glucagon-like peptide 1 (GLP-1) through a nov-
el two-pathway (B). GLP-1R, GLP-1 receptor; DPP-4, dipeptidyl 
peptidase-4, BP, blood pressure (Modified from Mudaliar S, et 
al. Am J Med 2009;122(6 Suppl):S25-36, and Ban K, et al. J Am 
Soc Hypertens 2009;3:245-59. Used with permission) [31,43]. 441
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SUMMARY
Current evidence on the effects of GLP-1 on various cardio-
vascular risk factors is summarized in Table 1 [44]. Incretin, 
especially the GLP-1–based compounds, appears to have car-
dioprotective potential independent of weight loss and glyce-
mic control. These cardioprotective effects might be mediated 
by the expression of the GLP-1R on a number of cardiac and 
vascular tissues and even by GLP-1R–independent signaling 
pathways. However, it remains uncertain if the cardiovascular 
actions of GLP-1 are mediated only by the GLP-1R because 
GLP-1 (9-36), the metabolite of GLP-1, shares many of the 
beneficial effects of GLP-1 in animal models but not in humans. 
While the clinical use of GLP-1R agonists and DPP-4 inhibi-
tors is increasing for the treatment of T2DM, these cardiopro-
tective effects are not the same as those observed with GLP-1. 
The human studies of incretin-based therapy detecting a car-
diovascular endpoint have been very limited so far. Larger, 
longer-term clinical studies are needed.
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